<DOC>
	<DOCNO>NCT00105157</DOCNO>
	<brief_summary>This study investigate safety efficacy different dose investigational drug ( MK0518 ) therapy HIV-infected patient fail current antiretroviral therapy .</brief_summary>
	<brief_title>Safety Efficacy Investigational Drug Human Immunodeficiency Virus ( HIV ) -Infected Patients Failing Current Antiretroviral Therapies ( 0518-005 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patient must HIV positive Human Immunodeficiency Virus ( HIV ) Ribonucleic Acid ( RNA ) value within range require study Patient must currently antiretroviral therapy ( ART ) Patient le 18 year age Additional exclusion criterion discuss identify study doctor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>